MacroGenics, Inc.
NASDAQ:MGNXBiotechnology
+$0.08 today
- Market cap
- $131.01M
- Beta
- 1.20
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$1.11
Volume 0.57M
Average 0.98M
MGNX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
MacroGenics, Inc.NASDAQ: MGNX
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $33.29M fell 12.2% year over year, ahead of the -19.9% change in trailing-twelve-month research & development. Sequentially, it rose 3.2% from the prior quarter. Over 3 fiscal years it compounded at -12.2% a year.
Context
- Research & development amounted to 93.6% of revenue in FY2025, down 25.8 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -12.2% holds above the trailing-twelve-month pace of -19.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 140M USD
- Year-over-year change
- -21.0%
- 4-year CAGR
- -10.1%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 140M | -21.0% |
| FY2024 | 2024-12-31 | 177.19M | +6.4% |
| FY2023 | 2023-12-31 | 166.58M | -19.5% |
| FY2022 | 2022-12-31 | 207.03M | -3.5% |
| FY2021 | 2021-12-31 | 214.58M | — |
Research & Development vs competitors
How MGNX compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -19.9% is the 7th highest of 11, against a peer median of -13.4%.
- Research & development amounts to 86.2% of revenue for MGNX, versus a peer median of 27954.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $3.68B USD | +26273.1% | +50.2% | 46313.4% | |
| LTM Mar 2026 | $135.36M USD | -19.9% | -12.2% | 86.2% | |
| LTM Mar 2026 | $108.76M USD | -25.2% | -14.7% | — | |
WHWKWhitehawk Therapeutics Inc | LTM Mar 2026 | $99.41M USD | +115.1% | +40.7% | — |
| FY2025 | $37.8M USD | +29.2% | -26.9% | 59059.4% | |
| LTM Mar 2026 | $36.3M USD | -40.4% | -24.8% | 3629.9% | |
| LTM Mar 2026 | $35.41M USD | +46.4% | +65.0% | — | |
| LTM Mar 2026 | $30.07M USD | -8.9% | +1.3% | 422.2% | |
| LTM Mar 2026 | €22.87M EUR | -34.8% | -11.8% | 77989.1% | |
| LTM Mar 2026 | $12.86M USD | -17.9% | -24.0% | 9596.3% | |
| LTM Mar 2026 | $5.77M USD | -21.5% | -38.7% | — | |
| Peer median (excluding MGNX) | — | -13.4% | -13.3% | 27954.8% | |
Competitors are the stored peer set for MGNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 75.64M | 150.02M | 57.19M | 148.34M | 149.5M |
| Cost of Revenue | 2.65M | 7.38M | 8.22M | 12.3M | 43.18M |
| Gross Profit | 72.99M | 142.63M | 48.97M | 136.04M | 106.32M |
| Gross Margin | 96.5% | 95.1% | 85.6% | 91.7% | 71.1% |
| Research & Development | 214.58M | 207.03M | 166.58M | 177.19M | 140M |
| Selling, General & Admin | 63.01M | 58.95M | 52.19M | 71.05M | 39.16M |
| Operating Expenses | 275.79M | 264.05M | 217.22M | 246.62M | 179.16M |
| Depreciation & Amortization | 11.26M | 11.87M | 9.65M | 7.54M | 7.17M |
| EBITDA | (190.86M) | (107.89M) | 2.02M | (57.37M) | (59.61M) |
| EBITDA Margin | -252.3% | -71.9% | 3.5% | -38.7% | -39.9% |
| Operating Income | (202.8M) | (121.42M) | (168.24M) | (110.58M) | (72.84M) |
| Operating Margin | -268.1% | -80.9% | -294.2% | -74.5% | -48.7% |
| Interest Income | 680K | 1.7M | 9.69M | 9.42M | 3.4M |
| Interest Expense | 0 | 0 | 1.43M | 1.12M | 8.51M |
| Other Income / Expenses | 680K | 1.66M | 159.19M | 44.56M | (2.45M) |
| Income Before Tax | (202.12M) | (119.76M) | (9.06M) | (66.02M) | (75.29M) |
| Pre-Tax Margin | -267.2% | -79.8% | -15.8% | -44.5% | -50.4% |
| Income Tax Expense | 0 | 0 | 0 | 944K | (672K) |
| Net Income | (202.12M) | (119.76M) | (9.06M) | (66.97M) | (74.62M) |
| Net Margin | -267.2% | -79.8% | -15.8% | -45.1% | -49.9% |
| EPS (Basic) | (3.18) | (1.95) | (0.15) | (1.07) | (1.18) |
| EPS (Diluted) | (3.18) | (1.95) | (0.15) | (1.07) | (1.18) |
| Weighted Avg Shares | 59.94M | 61.41M | 61.93M | 62.62M | 63.16M |
| Weighted Avg Shares (Diluted) | 59.94M | 61.43M | 61.93M | 62.62M | 63.16M |
MacroGenics, Inc.
NASDAQ:MGNX
Intrinsic Alpha fair value
Locked
Current Price
$2.05
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.